‘Teaching corner’: Management of Diabetic Retinopathy by Ellis, D et al.
Malawi Medical Journal; 25(4): 116-120 December 2013 Management of Diabetes 116
‘Teaching	corner’:	Management	of	Diabetic	Retinopathy
	 	 	 Abstract
Sub-Saharan Africa faces an epidemic of  diabetes.  Visual loss from 
diabetic retinopathy (DR) is both preventable and treatable.  This article 
reviews the epidemiology and clinical features of  DR and current evidence-
based interventions in three areas: primary prevention of  retinopathy 
by optimum medical management, early detection of  pre-symptomatic 
disease and management of  established retinopathy to prevent or mitigate 
visual loss.  There are significant challenges to DR care in resource poor 
environments.  Appropriate provision of  effective interventions by health 
services can reduce social and economic costs associated with patient care.
Introduction
International Diabetes Federation has estimated that the 
number of  adults with diabetes in Africa will expand by 
98%, from 12.1 million in 2010 to 23.9 million in 20301.
Diabetes causes visual impairment through early-onset 
cataract and diabetic retinopathy (DR), a progressive disease 
of  the retinal microvasculature.  Cataract and DR are the 
second and sixth leading causes of  global visual impairment, 
respectively2.  Both are included in the list of  nine target 
diseases of  Vision 2020, a joint programme of  WHO and 
the International Agency for the Prevention of  Blindness.
The 2009 WHO Malawi national STEPwise approach to 
surveillance (STEPS) survey estimated a prevalence of  
diabetes of  5.6% in adults aged 25 to 64 years. 90% of  
these have type II diabetes3.  Without intervention visual 
impairment as a result of  diabetes will increasingly impose 
social and economic burdens on communities in Malawi. 
Visual loss from diabetic retinopathy is both preventable and 
treatable.  Medical management of  diabetes, early detection 
of  retinopathy and timely treatment all diminish the risk of  
visual loss.
Who	is	at	risk	of	diabetic	retinopathy?	
Large cohort studies in Europe4 and the US5, 6 have 
demonstrated that the greatest risk factor for development of  
DR is duration of  diabetes.  The Wisconsin Epidemiologic 
Study of  Diabetic Retinopathy (WESDR) showed an 
increase in the prevalence of  DR from 17% in those having 
had diabetes for less than 5 years to 97.5% in those 15 
years and over. Proliferative retinopathy affected 1.2% in 
those having diabetes for less than 10 years, against 67% in 
those having it for 35 years or more6.  Two key studies, the 
Diabetes Control and Complications Trial (DCCT) (type 
I diabetes study)7 and the United Kingdom Prospective 
Diabetes Study (UKPDS) (type II diabetes study)8,9,10 
demonstrated additional risk factors for the development 
and progression of  DR:  glycaemic control (measured by 
HbA1c level) and hypertension.  The more recent Action to 
Control Cardiovascular Risk in Diabetes (ACCORD)11 and 
Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD)12 studies have highlighted the role of  blood lipid 
levels. The effect of  variables which are important in the 
Southern African context such as HIV and a high burden of  
infection with malaria are, at present, unknown.
What	retinal	changes	occur?
The retina is supplied by two circulatory systems: the uveal 
(choroidal) circulation and the retinal vasculature (Figure 
1). Diabetes damages retinal capillaries through prolonged 
exposure to hyperglycaemia. This leads to loss of  supporting 
pericyte cells and tight junctions between endothelial cells. 
Leakage from capillaries results in retinal oedema and 
capillary closure leads to ischaemia. 
Figure 1. Normal retinal anatomy.  The retinal vasculature radiates from 
the optic disc.  The macula is bordered by the vascular arcades.  Light 
is focused on the fovea which is responsible for sharp, central, colour 
vision.
Non-proliferative	diabetic	retinopathy
DR can be classified either non-proliferative (NPDR) or 
proliferative (PDR).  Non-proliferative DR is characterised 
by microaneurysms, intraretinal haemorrhages, venous 
beading and intraretinal microvascular abnormalities 
(IRMA). (Figure 2).  NPDR is usually asymptomatic but may 
progress to PDR.
Figure 2. Non-proliferative diabetic retinopathy. Colour fundus 
photograph showing haemorrhages (H), Cotton wool spots (CWS) 
and intraretinal microvascular abnormalities (IRMA). 
 
Proliferative	diabetic	retinopathy
Ischaemic retina produces growth factors including vascular 
endothelial growth factor (VEGF).  The growth of  abnormal 
new vessels is stimulated from the optic disc or retina.  New 
vessels are prone to bleeding (vitreous haemorrhage) and the 
accompanying fibrosis leads to tractional retinal detachment; 
both sight-threatening manifestations of  PDR. (Figure 3.)
Figure 3. Proliferative diabetic retinopathy. Colour fundus photograph 
showing (A) new vessels, (B) fibrovascular tissue and (C) a central 
retinal hole secondary to traction from fibrovascular tissue.
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Diabetic	Maculopathy
Retina which is oedematous or ischaemic loses function 
and this will reduce vision if  the central retina or macular 
is involved. Diabetic maculopathy can be divided into two 
types: macular oedema and macular ischaemia which may 
co-exist.  Macular oedema occurs due to breakdown of  the 
inner blood-retina barrier.  Fluid which accumulates within 
the retina distorts its architecture.  Deposition of  serum 
lipids, usually around the edges of  areas of  microvascular 
leakage, are seen as ‘exudates’ (Figure 4).  Exudates act as 
surrogate markers of  retinal thickening and oedema which 
can only be seen when the retina is viewed stereoscopically. 
Oedema is assessed clinically and using imaging technology 
(Figures 5 and 6).  Ischaemic maculopathy occurs due to 
capillary loss within the macula, is diagnosed by fluorescein 
angiography and is, at present, untreatable.
Figure 4. Colour fundus photograph showing extensive exudates 
some of which are grouped in ‘circinates’ surrounding clusters of 
microaneurysms (labelled C in image). 
Figure 5.  Imaging of diabetic macular oedema.  Mid (a) and late (b) 
phase fluorescein angiogram images showing leaking microaneurysms 
and pooling of dye in intraretinal spaces. 
Figure 6. (a) Red free image (left) showing location of scan on optical 
coherence tomography (OCT).  OCT (right) shows intraretinal fluid 
cysts with thickening of the retina and a detached hyaloid face. 
(b) Normal OCT image of  the central macula for comparison
How	can	diabetic	retinopathy	be	assessed?
DR remains asymptomatic until vision is affected but by this 
time the condition may be irreversible.  Treatment is most 
likely to be effective when performed before progression 
to advanced disease.  Slit-lamp examination by a trained 
ophthalmologist and retinal photography with grading of  
retinopathy by accredited graders can be considered the 
reference standards for disease detection.  Examination with 
the direct ophthalmoscope is less sensitive and specific for 
DR13.
Fluorescein angiography can also be used clinically to examine 
the circulation of  the retina and choroid. This method involves 
injecting a fluorescent dye and photographing the posterior 
section of  the eye using a specialised camera to obtain an 
angiogram. Hyperfluoresence angiograms are usually caused 
by leaking capillaries and abnormal vasculatures, including 
neovascularisation, with blocked capillaries being the main 
cause of  hypofluoresence.
How	is	diabetic	retinopathy	managed?
Risk of  visual loss from DR is reduced by interventions which 
fall into 3 categories: primary prevention of  microvascular 
complications, early detection of  retinopathy and effective 
treatment of  established disease.
Primary	prevention
Glycaemic	control
Risk of  microvascular complications of  diabetes are reduced 
by optimum glycaemic control.  After mean duration of  
follow-up 6.5 years the DCCT achieved a reduction in mean 
HbA1c from 9.1% to 7.3% with reduction in progression 
of  retinopathy of  76%14.  After a mean duration of  follow-
up of  10 years in the UKPDS reduction of  HbA1c 7.9% 
to 7.0% was associated with a 25% risk reduction of  
microvascular complications8.  Both DCCT and UKPDS 
demonstrated legacy effects. In the DCCT after ten years 
follow-up where the glycosylated haemoglobin levels had 
converged completely, the former intensive treatment group 
still had 24% reduction in progression of  retinopathy and 
59% reduction in proliferative retinopathy15.  However, 
very tight glycaemic control was associated with increased 
mortality in the ACCORD study [11].  Current guidelines 
suggest target HbA1c between 6.5 – 7.0 %16, however a 
target HbA1c of  < 7.0% for type I diabetics and < 7.5% for 
type II diabetics is more suitable. This is because lower blood 
glucose targets are associated with increased mortality due to 
some patients’ inability to tolerate hypoglycaemia as well as 
there being limited access to treatment for hypoglycaemic, 
diabetic patients in Malawi.Control of  hypertension
Blood pressure control plays an important role in prevention 
and management of  diabetic retinopathy.  The UKPDS 
compared the control of  hypertension in type II diabetic 
patients.  A ‘tightly controlled’ group were treated with 
either a beta blocker or ACE inhibitor aiming for a BP below 
150/85 mmHg. A less tight BP control group aimed for a BP 
below 180/105 mmHg. Following 7 years the tight control 
group showed a 34% reduction in the rate of  progression in 
DR, a 47% reduction in visual loss and had 35% less need 
of  laser photocoagulation compared to the less tight group10. 
Specific therapies blocking the renin-angiotensin system may 
have additional benefits, particularly for mild retinopathy, 
but should be discontinued during pregnancy16. 
Lipid	lowering	agents
Observational data from the Early Treatment of  Diabetic 
Retinopathy Study (ETDRS) suggest that elevated total 
serum cholesterol levels are associated with an increased 
risk of  visual loss in patients with diabetic retin¬opathy17. 
The possibility of  an effect of  statins was investigated in 
the Collaborative Atorvastatin Diabetes Study (CARDS) 
[18].  Results were encouraging but the effect appears to 
be small.  The FIELD study assessed the effects of  long 
term lipid-lowering therapy with fenofibrate on reducing 
the progression of  DR and the need for laser treatment. It 
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found that fewer patients receiving fenofibrate required laser 
treatment (3.4%) than those in the control group (4.9%). 
Interestingly benefits were not related to changes in lipid 
levels so the mechanism of  drug action remains unclear.  
The ACCORD randomised trial, investigated whether 
intensive glycaemic control, combination therapy for 
dyslipidaemia and intensive blood-pressure control, would 
limit DR progression in type II diabetes. The rate of  DR 
at 4 years being 6.5% for the fenofibrate group and 10.2% 
for the placebo. Moderate vision loss was seen in 23.7% and 
24.5% of  participants in the fenofibrate and placebo groups 
respectively [11].  Currently, the recommended serum lipid 
levels for diabetic patients are: an optimal LDL cholesterol 
concentration of  <100 mg/dl, optimal HDL cholesterol 
level of  >45 mg/dl and desirable triglycerides levels of  <150 
mg/dl19.
Other	medical	interventions
Glitazones are effective at lowering glycosylated haemoglobin 
but their use is limited due to adverse effects.  These agents 
were associated in a large case series with 2.6 fold in macular 
oedema20.  Current advice is to withdraw pioglitazone when 
macula oedema has developed16.  The effects of  protein 
kinase C activation and its inhibition on treating DR and 
diabetic macular oedema are currently being investigated. 
Two studies, using the protein kinase C β-inhibitor, 
Ruboxistaurin, have compared visual loss in diabetic macular 
oedema and DR with moderately encouraging results21,22. 
Although smoking contributes to other complications of  
diabetes no clear association of  smoking and retinopathy has 
been demonstrated. Counselling and treatment for smoking 
is cost effective in diabetes management23 and a lack of  
benefit for DR should not alter advice to patients to stop 
smoking.
Screening	for	diabetic	retinopathy
Diabetic retinopathy meets the WHO criteria for a 
screening programme: an important public health issue; a 
recognised pre-symptomatic stage; an acceptable screening 
procedure and an effective treatment.  At present persons 
with diabetes are advised to attend for retinal examination 
every 12 months16.  Systematic screening is shown to be 
cost-effective for sight years preserved compared with no 
screening in developed countries24.  Variation in age of  onset 
of  diabetes, glycaemic control, sensitivity of  the screening 
test and compliance rates influence the cost-effectiveness of  
screening programmes.  Optimum screening intervals have 
yet to be defined and research on targeted screening based 
on disease risk factors is on-going.
Currently there is no systematic screening programme for DR 
in Malawi.  There have been scattered reports of  successful 
attempts to screen patients attending diabetes clinics for 
DR in Africa25,26 including the ‘LEOPARD’ programme in 
Ethiopia (Paul Dodson personal communication).  Mumba 
et al26 in Tanzania attempted to develop a register of  known 
patients with diabetes.  Defining an eligible population is 
an essential component of  a screening programme but is a 
challenge in resource poor settings. Digital photography with 
telemedicine links, as used by the English national screening 
programme27, has the potential to deliver cost effective, 
accessible screening to rural and remote populations. 
Unfortunately fundus cameras remain prohibitively 
expensive.  Development of  lower cost solutions could 
radically alter the landscape for DR care in Africa; research 
into appropriate technologies is needed.  Automated fundus 
photograph analysis is an exciting innovation which has the 
potential to reduce the cost of  screening programmes.
Treatments	for	sight	threatening	retinopathy
Despite the fact that the majority of  patients with 
retinopathy do not require treatment, regular eye checks 
are required to assess whether or not intervention is 
required to prevent sight deterioration.  The development 
of  sight threatening maculopathy, severe non-proliferative 
retinopathy or proliferative retinopathy necessitates referral 
to an ophthalmologist.
Laser	photocoagulation
The effectiveness of  laser photocoagulation at reducing the 
likelihood of  visual impairment and blindness in patients 
with proliferative diabetic retinopathy (PDR) and macular 
edema is well established.  Laser for PDR involves ablation of  
peripheral retina with 1 to 5 thousand spaced burns to reduce 
the amount of  ischaemic retina and VEGF it produces. The 
Diabetic Retinopathy Study was a multi-centre randomised 
trial evaluating the use of  scatter photocoagulation in 
reducing visual loss in PDR.  PRP reduced visual loss 
by 50% compared to no treatment28.  Laser for diabetic 
macular oedema involves treatment directly to leaking 
microaneurysms, and gentle laser (up to 300 burns) to the 
macula, thought to stimulate cellular fluid pumps. Laser 
cannot treat vision lost due to ischemic maculopathy.  The 
ETDRS compared laser photocoagulation with observation 
for diabetic macular oedema. After a 3 year period, there was 
a reduction from 24% to 12% in moderate visual loss for the 
laser group.  Following treatment, visual acuity improved in 
only 3% of  those treated29.
In Malawi laser treatment is now available in the public 
sector at Lions Sight First Eye Units at both Kamuzu Central 
Hospital, Lilongwe and Queen Elizabeth Central Hospital, 
Blantyre.  In Blantyre dedicated referral clinics can be 
accessed by doctors and ophthalmic clinical officers.  Annual 
training for ophthalmic clinical officers in recognition 
and referral of  DR is run in conjunction with the QECH 
Department of  Medicine.
Intravitreal	steroids
Laser photocoagulation is insufficient alone to prevent visual 
loss in all cases of  diabetic macular oedema.  Intravitreal 
triamcinolone acetonide (IVTA) has been investigated as 
a monotherapy and as an adjunct to laser.  There is good 
evidence that IVTA monotherapy is inferior to laser 
treatment at 3 year follow-up30.  The Diabetic Retinopathy 
Clinical Research Network (DRCR.net) demonstrated 
that IVTA combined with laser is inferior to ranibizumab 
with immediate or deferred laser, except in patients who 
are pseudophakic31.  Flucinolone slow release intravitreal 
implant is effective in macular oedema32.  Intravitreal steroid 
preparations are associated with a high incidence of  raised 
intra-ocular pressure and cataract.
Intravitreal	anti-VEGF	agents
Levels of  vascular endothelial growth factor (VEGF) are 
elevated in the vitreous and retina in patients with DR and 
diabetic macular oedema33.  Recent evidence demonstrates 
better short-term outcomes than laser alone for intra-vitreal 
monoclonal antibody therapies targeting the VEGF molecule 
in diabetic maculopathy which has already reduced vision. 
The 2010 landmark DRCR.net study34 compared intravitreal 
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ranibizumab with prompt macular laser photocoagulation, 
ranibizumab with deferred laser photocoagulation, IVTA 
with prompt laser, or a sham injection with prompt laser. 
At 2 years, intravitreal ranibizumab combined with either 
prompt or deferred laser, showed superior improvements in 
best corrected visual acuity compared with laser treatment 
alone. There was a gain of  at least 15 ETDRS letters in 
around 30% of  patients in each of  the ranibizumab arms, 
15% for the laser monotherapy group, and 21% for the 
triamcinolone group.
Anti-VEGF agents, which require multiple repeat injections, 
will be increasingly used in resource-rich countries although 
with a continued role for laser.  At present these agents 
are prohibitively expensive for widespread use in resource-
poor countries (approximately US$800 per injection for the 
drug alone).  However off-label use of  the systemic anti-
VEGF, bevacizumab (US$~70 per injection), is used in 
some African tertiary centres on a paying patient basis, an 
approach supported by the ‘BOLT’ study35. 
Surgical	management	of	diabetic	retinopathy
Vitreoretinal surgery has an important role in managing 
advanced disease to mitigate visual loss.  The objectives of  
surgical removal of  the vitreous (vitrectomy) include removal 
of  vitreous opacity (commonly blood) and/or fibrovascular 
proliferation, relieving retinal traction, achieving retinal 
reattachment, and allowing completion of  scatter laser 
photocoagulation.  A large case series showed that sight 
threatening complications are rare and in approximately 90% 
of  cases, vision is improved or stabilised36.  Vitrectomy may 
also be beneficial in maculopathy in cases where traction from 
the vitreous contributes to fluid accumulation.  Currently 
vitreoretinal surgery is not available in Malawi.
What	are	the	specific	challenges	for	Malawi?
The best evidence currently available suggests that, of  
patients attending diabetes clinics in Malawi, approximately 
20% have sight threatening diabetic retinopathy (STDR) 
and 5% proliferative diabetic retinopathy37 (approximately 3 
times and 5 times levels reported in recent European and 
American studies, respectively).  The burden of  diabetes and 
its complications is borne predominantly by the working age 
population38.  A disease which reduces the economic activity 
of  this group affects individual, household and national 
economies.  Diabetes care must compete in the political 
spectrum with other financial and health care initiatives. 
It does not lend itself  to vertical programmes favoured 
by donors.  However political attention is turning to non 
communicable disease (NCD) as witnessed by the UN high 
level meeting on NCD prevention and control, Sept 201139. 
The challenges for effective management of  diabetes in sub-
Saharan Africa have been recently reviewed by our group40. 
Policy makers require evidence based guidance on resource 
allocation.
Conclusion
Visual loss from diabetic retinopathy is both preventable 
and treatable. Effective and consistent medical management 
reduces incidence and progression of  retinopathy. Detection 
of  early, pre-symptomatic disease allows timely treatment 
with laser photocoagulation to prevent visual loss.  If  
vision is lost, treatment with vitreoretinal surgery or agents 
injected intra-ocularly may stabilise or improve vision. 
There are significant challenges to DR care in resource 
poor environments.   However, the improved provision 
of  effective, evidence-based interventions by health 
professionals involved with diabetes care can reduce the 
social and economic impact on patients.
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